Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 50 of 67 Next >>

Filter Applied: adverse drug reaction (Click to remove)

Burning Pain in the Legs
NEJM 383:e18, Sacks, C.A., 2020

Toxoplasmosis in HIV-Infected Patients
www.UptoDate.com, May, Gandhi, R.T., 2019

Varicella-Zoster Virus Infections in Patients Treated with Fingolimod
JAMA Neurol 72:31-39,10, Arvin, A.M.,et al, 2015

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 373:1418-1428, Kappos, L.,et al, 2015

Preexposure Prophylaxis for HIV - Where Do We Go from Here?
NEJM 367:459-461,462, Cohen, M.S. & Baden, L.R., 2012

Prevention of HIV-1 Infection with Early Antiretroviral Therapy
NEJM 365:493-505,561, Cohen, M.S.,et al, 2011

PML-IRIS in Patients with HIV Infection: Clinical Manifestations and Treatment with Steroids
Neurol 72:1458-1464,1454, Tan,K.,et al, 2009

Herpes Simplex Encephalitis during Treatment with Tumor Necrosis Factor- Inhibitors
CID 49:924-927, Bradford, R.D.,et al, 2009

Interferon �-Associated Retinopathy in Patients Treated for Multiple Sclerosis
Neurol 70:1153-1155, Folden,D.V.,et al, 2008

Combining Beta Interferon and Atorvastatin May Increase Disease Activity in Multiple Sclerosis
Neurol 71:1390-1395,1386, Birnbaum,G.,et al, 2008

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008

Reversible Posterior Leukoencephalopathy Syndrome in 2 HIV-Infected Patients Receiving Antiretroviral Therapy
CID 49:e19-e22, Ridolfo, A.L.,et al, 2008

Facial Weakness in a Haemodialysis Patient
Lancet 369:714, Papadakis,M.,et al, 2007

Neutralizing Antibodies to Interferon Beta: Assessment of Their Clinical and Radiographic Impact: An Evidence Report
Neurol 68:977-984, Goodin,D.S.,et al, 2007

Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006

Progressive Multifocal Leukoencephalopathy Revisited: Has the Disease Outgrown Its Name?
Ann Neurol 60:162-173, Koralnik,I.J., 2006

Interferon beta-1a Treatment in Childhood and Juvenile-Onset Multiple Sclerosis
Neurol 67:511-513, Tenembaum,S.N. &Segura,M.J., 2006

Treatment of Early Onset Multiple Sclerosis With Subcutaneous Interferon Beta-1a
Neurol 64:888-890, 778, Pohl,D., et al, 2005

Cerebral MR Imaging in Uninfected Children Born to HIV-Seropositive Mothers and Perinatally Exposed to Zidovudine
AJNR 26:695-701,687, Tardieu,M.,et al, 2005

Rhabdomyolysis: An Evaluation of 475 Hospitalized Patients
Medicine 84:377-385, Melli,G.,et al, 2005

Liver Injury Associated with the B-Interferons for MS
Neurol 62:628-631, Tremlett,H.L.,et al, 2004

Vasculitic Mononeuritis Multiplex Induced by Valcyclovir
Neurol 62:1906-1907, Pary,L.F.,et al, 2004

Interferons in Relapsing Remitting Multiple Sclerosis: A Systematic Review
Lancet 361:545-552, Filippini,G.,et al, 2003

Recombinant Interferon-a-induced Chorea and Frontal Subcortical Dementia
Neurol 58:328-330, Moulignier,A.,et al, 2002

Interferon Beta but not Glatiramer Acetate Therapy Aggravates Headaches in MS
Neurol 59:636-639, Pollmann,W.,et al, 2002

Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management
The Neurologist 8:227-236, Frohman,E.,et al, 2002

Fulminant Liver Failure During Interferon Beta Treatment of Multiple Sclerosis
Neurol 56:1416, Yoshida,E.M.,et al, 2001

Adverse Effects of Antiretroviral Therapy
Lancet 356:1423-1430, Carr,A. &Cooper, D.A., 2000

Multiple Sclerosis,Therapeutic Update
Arch Neurol 56:277-280, Tselis,A.C.&Lisak,R.P., 1999

Severe Anaphylaxis with Recombinant Interferon Beta
Neurol 52:425, Corona,T.,et al, 1999

Ibuprofen Treatment Versus Gradual Introduction of Interferon B-1b in patients with MS
Neurol 52:1893-1895, Rice,G.P.A.,et al, 1999

Evidence of Interferon B-1a Dose Response In Relapsing-Remitting MS, The OWIMS Study
Neurol 53:679-686, The Once Weekly Interferon for MS Study Group (OWI, 1999

Multiple Sclerosis, Side Effects of Interferon Beta Therapy and Their Management
Neurol 53:1622-1627, Walther,E.U.&Hohlfeld,R., 1999

Interferon Treatment for Multiple Sclerosis:Autoimmune Complications May be Lethal
Neurol 50:570-571, Durelli,L.,et al, 1998

HIV-Protease Inhibitors
NEJM 338:1281-1292, Flexner,C., 1998

Spastic Diplegia as a Complication of Interferon Alfa-2a Treatment of Hemangiomas of Infancy
J Pediatr 132:527-530, Barlow,C.F.,et al, 1998

Lipodystrophy Associated with an HIV-Protease Inhibitor
NEJM 339:1296, Carr,A.&Cooper,D.A., 1998

Buffalo Hump in a Patient with the Acquired Immunodeficiency Syndrome
NEJM 339:1297, Aboulafia,D.M.&Bundow,D., 1998

Current Immunotherapy in Multiple Sclerosis
Immunology and Cell Biology 76:55-64, Bashir,K.&Whitaker,J.N., 1998

Drugs and Myasthenia Gravis, An Update
Arch Int Med 157:399-408, Wittbrodt,E.T., 1997

Hearing Loss and Antiretroviral Therapy in Patients Infected with HIV-1
Arch Neurol 54:407-410, Marra,C.M.,et al, 1997

Anticytokine Antibodies in Beta Interferon-Trated MS Patients and the Need for Testing
Neurol 49:647-650, Pachner,A.R., 1997

Management of Multiple Sclerosis
NEJM 337:1604-1611, Rudick,R.A.,et al, 1997

Management of Patients Receiving Interferon Beta-1b for MS:Report of a Consensus Conf
Neurol 46:12-18, Lublin,F.D.,et al, 1996

Transient Ara-C Leukoencephalopathy:MR Findings
J Comput Assist Tomogr 20:161-169, Patel,A.G.&Rao,R., 1996

Side Effect Profile of Interferon Beta-1b in MS:Results of an Open Label Trial
Neurol 46:552-554, Neilley,L.K.,et al, 1996

Ganciclovir-Induced Psychosis
NEJM 335:1937, Hansen,B.A.,et al, 1996

Neutralizing Antibodies During Treatment of Multiple Sclerosis with Interferon Beta-1b
IFNB MS Study Group & UBC MS. MRI Analysis Group, Neurol 47:889-8946., , 1996

Guidelines for Physicians with Patients on IFNB-1b:The Use of an Assay for Neutralizing Antibodies (NAB)
Neurol 47:865-866, Paty,D.,et al, 1996



Showing articles 0 to 50 of 67 Next >>